Top-Rated StocksTop-RatedMost-Downgraded StocksMost-DowngradedNASDAQ:TXG 10x Genomics (TXG) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free TXG Stock Alerts $26.92 -2.36 (-8.06%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$24.60▼$27.4950-Day Range$26.90▼$47.1652-Week Range$24.60▼$63.57Volume6.51 million shsAverage Volume1.68 million shsMarket Capitalization$3.21 billionP/E RatioN/ADividend YieldN/APrice Target$48.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get 10x Genomics alerts: Email Address 10x Genomics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.58 Rating ScoreUpside/Downside80.2% Upside$48.50 Price TargetShort InterestBearish7.44% of Shares Sold ShortDividend StrengthN/ASustainability-0.73Upright™ Environmental ScoreNews Sentiment-0.07Based on 27 Articles This WeekInsider TradingSelling Shares$592,806 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.47) to ($0.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.47 out of 5 starsMedical Sector102nd out of 926 stocksAnalytical Instruments Industry4th out of 26 stocks 4.3 Analyst's Opinion Consensus Rating10x Genomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 8 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst Coverage10x Genomics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.44% of the outstanding shares of 10x Genomics have been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in 10x Genomics has recently increased by 4.11%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend Yield10x Genomics does not currently pay a dividend.Dividend Growth10x Genomics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) Score10x Genomics has received a 76.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biochemical assay kits", "Microfluidic biochips", and "Workflow automation software for clinical laboratories" products. See details.Environmental SustainabilityThe Environmental Impact score for 10x Genomics is -0.73. Previous Next 2.2 News and Social Media Coverage News Sentiment10x Genomics has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 27 news articles for 10x Genomics this week, compared to 4 articles on an average week.Search Interest12 people have searched for TXG on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.MarketBeat Follows9 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $592,806.00 in company stock.Percentage Held by Insiders10.65% of the stock of 10x Genomics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for 10x Genomics are expected to grow in the coming year, from ($1.47) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 10x Genomics is -12.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 10x Genomics is -12.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio10x Genomics has a P/B Ratio of 4.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About 10x Genomics Stock (NASDAQ:TXG)10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Read More TXG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TXG Stock News HeadlinesMay 2, 2024 | finanznachrichten.de10x Genomics, Inc: 10x Genomics Reports First Quarter 2024 Financial ResultsMay 2, 2024 | americanbankingnews.com10x Genomics (NASDAQ:TXG) Sets New 12-Month Low After Analyst DowngradeMay 2, 2024 | Chaikin Analytics (Ad)A.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.May 1, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)May 1, 2024 | americanbankingnews.comCanaccord Genuity Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $50.00May 1, 2024 | finance.yahoo.com10x Genomics Inc (TXG) (Q1 2024) Earnings Call Transcript Highlights: Diverse Revenue Streams ...May 1, 2024 | businesswire.comCurio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)April 30, 2024 | sfgate.com10x Genomics: Q1 Earnings SnapshotMay 2, 2024 | Chaikin Analytics (Ad)A.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.April 30, 2024 | markets.businessinsider.comTXG Stock Earnings: 10x Genomics Meets EPS, Misses Revenue for Q1 2024April 30, 2024 | finance.yahoo.com10x Genomics Inc (TXG) Q1 2024 Earnings: Misses Analyst Expectations Amidst New Product LaunchesApril 30, 2024 | prnewswire.com10x Genomics Reports First Quarter 2024 Financial ResultsApril 29, 2024 | markets.businessinsider.com10x Genomics A is about to announce its earnings — here's what Wall Street expectsApril 29, 2024 | finance.yahoo.comThe Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorpApril 27, 2024 | americanbankingnews.com10x Genomics (NASDAQ:TXG) Sets New 1-Year Low at $26.48April 25, 2024 | americanbankingnews.com10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of "Moderate Buy" by BrokeragesApril 23, 2024 | americanbankingnews.com10x Genomics (TXG) Set to Announce Earnings on TuesdayApril 21, 2024 | nasdaq.comFirst Week of TXG June 21st Options TradingApril 17, 2024 | finance.yahoo.com10x Genomics, Inc. (TXG)April 11, 2024 | investing.comCathie Wood's ARK focuses on Teladoc and 10X Genomics stockApril 10, 2024 | finance.yahoo.com10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024April 10, 2024 | prnewswire.com10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024March 26, 2024 | finance.yahoo.com10x Genomics Commercially Launches Visium HD Spatial Gene Expression AssayMarch 23, 2024 | finanznachrichten.de10x Genomics, Inc: 10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene PanelMarch 21, 2024 | finance.yahoo.com10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene PanelMarch 16, 2024 | ca.finance.yahoo.comTXG Nov 2024 40.000 putMarch 16, 2024 | ca.finance.yahoo.comTXG Aug 2024 60.000 callSee More Headlines Receive TXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today5/02/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:TXG CUSIPN/A CIK1770787 Webwww.10xgenomics.com Phone925-401-7300FaxN/AEmployees1,259Year FoundedN/APrice Target and Rating Average Stock Price Target$48.50 High Stock Price Target$75.00 Low Stock Price Target$26.00 Potential Upside/Downside+115.5%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-255,100,000.00 Net Margins-41.17% Pretax Margin-40.21% Return on Equity-28.82% Return on Assets-22.67% Debt Debt-to-Equity RatioN/A Current Ratio4.69 Quick Ratio4.11 Sales & Book Value Annual Sales$618.73 million Price / Sales5.18 Cash FlowN/A Price / Cash FlowN/A Book Value$6.22 per share Price / Book4.33Miscellaneous Outstanding Shares119,167,000Free Float106,476,000Market Cap$3.21 billion OptionableOptionable Beta1.90 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Serge Saxonov Ph.D. (Age 47)Co-Founder, CEO & Director Comp: $837.68kDr. Benjamin J. Hindson Ph.D. (Age 49)Co-Founder, President, Chief Scientific Officer & Director Comp: $615.96kMr. Justin J. McAnear (Age 48)Chief Financial Officer Comp: $535.91kMr. Eric S. Whitaker Esq. (Age 57)Chief Legal Officer Comp: $558.97kMr. Michael Schnall-LevinFounding Scientist & CTOMs. Cassie CorneauManager of Investor Relations and Strategic FinanceMs. Rebecca PortChief People OfficerMore ExecutivesKey CompetitorsOlink Holding AB (publ)NASDAQ:OLKEyePoint PharmaceuticalsNASDAQ:EYPTBerkeley LightsNASDAQ:BLIBio-Rad LaboratoriesNYSE:BIO.BBio-Rad LaboratoriesNYSE:BIOView All CompetitorsInsiders & InstitutionsBaillie Gifford & Co.Sold 495,210 shares on 5/1/2024Ownership: 6.230%Mirae Asset Global Investments Co. Ltd.Bought 231,697 shares on 5/1/2024Ownership: 0.268%Capstone Investment Advisors LLCBought 10,589 shares on 5/1/2024Ownership: 0.014%Perigon Wealth Management LLCBought 4,512 shares on 4/30/2024Ownership: 0.012%Allspring Global Investments Holdings LLCBought 371 shares on 4/30/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions TXG Stock Analysis - Frequently Asked Questions Should I buy or sell 10x Genomics stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TXG shares. View TXG analyst ratings or view top-rated stocks. What is 10x Genomics' stock price target for 2024? 12 brokers have issued 12 month price objectives for 10x Genomics' shares. Their TXG share price targets range from $26.00 to $75.00. On average, they expect the company's share price to reach $48.50 in the next twelve months. This suggests a possible upside of 80.2% from the stock's current price. View analysts price targets for TXG or view top-rated stocks among Wall Street analysts. How have TXG shares performed in 2024? 10x Genomics' stock was trading at $55.96 at the beginning of 2024. Since then, TXG stock has decreased by 51.9% and is now trading at $26.92. View the best growth stocks for 2024 here. When is 10x Genomics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our TXG earnings forecast. How were 10x Genomics' earnings last quarter? 10x Genomics, Inc. (NASDAQ:TXG) issued its quarterly earnings data on Tuesday, April, 30th. The company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). The company earned $141.01 million during the quarter, compared to analysts' expectations of $142.24 million. 10x Genomics had a negative net margin of 42.20% and a negative trailing twelve-month return on equity of 30.43%. 10x Genomics's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.44) earnings per share. What ETFs hold 10x Genomics' stock? ETFs with the largest weight of 10x Genomics (NASDAQ:TXG) stock in their portfolio include Sprott Junior Gold Miners ETF (SGDJ), ARK Genomic Revolution ETF (ARKG), Sprott Gold Miners ETF (SGDM), U.S. Global GO GOLD and Precious Metal Miners ETF (GOAU), Global X Genomics & Biotechnology ETF (GNOM), Global X Gold Explorers ETF (GOEX), ARK Innovation ETF (ARKK) and Tema Oncology ETF (CANC). What guidance has 10x Genomics issued on next quarter's earnings? 10x Genomics issued an update on its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $670.0 million-$690.0 million, compared to the consensus revenue estimate of $677.8 million. What is Serge Saxonov's approval rating as 10x Genomics' CEO? 25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did 10x Genomics IPO? 10x Genomics (TXG) raised $297 million in an IPO on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager. Who are 10x Genomics' major shareholders? 10x Genomics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (6.23%), Sumitomo Mitsui Trust Holdings Inc. (3.04%), Mirae Asset Global Investments Co. Ltd. (0.27%), Assenagon Asset Management S.A. (0.05%), Mirador Capital Partners LP (0.02%) and Principal Financial Group Inc. (0.02%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, James Wilbur, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju. View institutional ownership trends. How do I buy shares of 10x Genomics? Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TXG) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
